iRadimed Posts Q2 EPS of 41c, Beating Expectations
IRMD sits 65% above its 52-week low of $57.58.
Summary
iRadimed reported second-quarter earnings per share of 41 cents, beating expectations, with revenue of $20.5 million. The company, which has a market cap around $1.2 billion, provided third-quarter guidance including EPS of 49 to 54 cents, adjusted EPS of 54 to 59 cents, and revenue of $23.0 million to $24.5 million. iRadimed also backed its 2026 outlook, reaffirming revenue of $91.0 million to $96.0 million and EPS of $1.90 to $2.05. The strong Q2 results and positive guidance are likely to drive favorable price action.
At the time of this announcement, IRMD was trading at $95.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $57.58 to $107.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.